| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/04/2004 | WO2003011114A3 Methods for treating prostatitis |
| 03/04/2004 | WO2003000846A3 A novel g protein-coupled receptor, gave 3 |
| 03/04/2004 | WO2003000268A8 Use of na+ channel blockers and aspirin in manufacturing drugs for producing analgesia synergistically in mammals |
| 03/04/2004 | WO2002092762A3 Cytokine polypeptides |
| 03/04/2004 | WO2002085459A3 Antiangiogenic combination therapy for the treatment of cancer |
| 03/04/2004 | WO2002085248A3 Prostanoids augment ocular drug penetration |
| 03/04/2004 | WO2002022134A8 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/04/2004 | WO2002012502A9 Anti-tnf antibodies, compositions, methods and uses |
| 03/04/2004 | US20040044272 Personal condition management system |
| 03/04/2004 | US20040044221 Anticancer ganets; drug resistance |
| 03/04/2004 | US20040044203 Anticancer agents |
| 03/04/2004 | US20040044194 Aggrecanase molecules |
| 03/04/2004 | US20040044184 Comprises cytoskeletal protein for diagnosis, prevention and treatment of cell proliferative, viral and neurodegenerative diseases |
| 03/04/2004 | US20040044082 Adrenergic receptor antagonist |
| 03/04/2004 | US20040044080 Treatment of dyspareunia with topically administered nitroglycerin formulations |
| 03/04/2004 | US20040044077 Agents for inhibiting or restoring skin damage caused by drying and method for evaluating the same |
| 03/04/2004 | US20040044069 Anti-virus compounds |
| 03/04/2004 | US20040044064 Administering melatonin, or antagonist thereof; uniform blood concentration |
| 03/04/2004 | US20040044051 Cannabinoid receptor agonists |
| 03/04/2004 | US20040044049 Compounds for inhibiting insulin secretion and methods related thereto |
| 03/04/2004 | US20040044018 Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor |
| 03/04/2004 | US20040044016 Antiviral agents |
| 03/04/2004 | US20040044005 Nicotine addiction treatment |
| 03/04/2004 | US20040044003 Therapeutic agents useful for treating pain |
| 03/04/2004 | US20040044001 Use of II-1 inhibitors for treating II-1 mediated diseases |
| 03/04/2004 | US20040043989 Therapy for drug resistant bacteria; topoisomerase inhibitor |
| 03/04/2004 | US20040043980 Bactericides; storage stability |
| 03/04/2004 | US20040043975 Skin disorders; mixture of diclofenas and enzyme inhibitor |
| 03/04/2004 | US20040043971 Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
| 03/04/2004 | US20040043962 Method for enhancing the effectiveness of cancer therapies |
| 03/04/2004 | US20040043959 Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| 03/04/2004 | US20040043927 Wound healing agents; anticancer agents; cardiovascular disorders |
| 03/04/2004 | US20040043919 Method for the treatment of neurological and neuropsychological disorders |
| 03/04/2004 | US20040043411 DSP-11 dual-specificity phosphatase |
| 03/04/2004 | US20040043087 Activation of mask cells; synergistic mixture of anticancer drug |
| 03/04/2004 | US20040043072 Alleviation of upper gastrointestinal irritation |
| 03/04/2004 | US20040043054 Composition and method to augment and sustain neurotransmitter production |
| 03/04/2004 | US20040043048 Cosmetic containing anti-bacterial agent and process for production thereof |
| 03/04/2004 | US20040043041 Antimicrobial compositions and methods of use |
| 03/04/2004 | US20040043013 Metabolic uncoupling therapy |
| 03/04/2004 | US20040043012 Lactic acid bacteria cultures that inhibit food-borne pathogens |
| 03/04/2004 | US20040042990 Composition containing oxidation-sensitive hydrophilic active principle and maleic anhydride copolymer, and use thereof |
| 03/04/2004 | US20040042960 Use of moulding compounds for producing treatment devices |
| 03/04/2004 | DE10240923A1 Flavonoid-Derivate zur Ekzem-Behandlung Flavonoid derivatives for eczema treatment |
| 03/04/2004 | CA2496831A1 Treating alzheimers using delipidated protein particles |
| 03/04/2004 | CA2496781A1 Methods for treating patients and identifying therapeutics |
| 03/04/2004 | CA2496686A1 A pharmaceutical preparation containing palladium complex compounds and the uses thereof for treating cancer and autoimmune disease |
| 03/04/2004 | CA2496572A1 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix |
| 03/04/2004 | CA2496485A1 Use of an anti-g-csf or anti-g -csfr antibody or a soluble g- csfr for the treatment or prophylaxis of arthritis |
| 03/04/2004 | CA2496376A1 Methods of drug delivery using sulphated chitinous polymers |
| 03/04/2004 | CA2496364A1 Composition for the carrying and delivery of bone growth inducing material and methods for producing and applying the composition |
| 03/04/2004 | CA2496272A1 Integrin b6 markers for compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer |
| 03/04/2004 | CA2496236A1 Preventives/remedies for cancer |
| 03/04/2004 | CA2495799A1 Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist |
| 03/04/2004 | CA2495796A1 Nutritional supplement for children |
| 03/04/2004 | CA2495682A1 Method for the prevention and/or treatment of atherosclerosis |
| 03/04/2004 | CA2495376A1 Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
| 03/04/2004 | CA2495354A1 An agent for inhibiting articular cartilage extracellular matrix degradation |
| 03/04/2004 | CA2494210A1 Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
| 03/04/2004 | CA2493747A1 Use of a ppar-alpha agonist to treat weight gain associated with a ppar-gamma agonist treatment |
| 03/03/2004 | EP1394551A2 Integrin as a predictor of endometriosis |
| 03/03/2004 | EP1394274A2 Methods of testing for bronchial asthma or chronic obstructive pulmonary disease |
| 03/03/2004 | EP1394175A1 Inhibitors of interleukin-1beta converting enzyme |
| 03/03/2004 | EP1393750A2 Conjugates for treating an immune disease |
| 03/03/2004 | EP1393733A1 Flavonoid-derivate for the treatment of eczema |
| 03/03/2004 | EP1393730A2 Combination chemotherapy involving topotecan and a platinum coordination compound |
| 03/03/2004 | EP1393729A2 Combination chemotherapy involving topotecan and a platinum coordination compound |
| 03/03/2004 | EP1393723A2 Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces |
| 03/03/2004 | EP1393722A2 Use of angiotensin II subtype 1 (AT1) antagonists for the manufacture of a medicament in the treatment of premenstrual syndrome |
| 03/03/2004 | EP1393277A1 Use of nfkb inhibitors to treat dry eye disorders |
| 03/03/2004 | EP1393077A2 Method for identifying ligands for g protein coupled receptors |
| 03/03/2004 | EP1393075A2 Methods of screening and using inhibitors of angiogenesis |
| 03/03/2004 | EP1392852A2 Nucleic acid-associated proteins |
| 03/03/2004 | EP1392849A2 Yeast screens for agents affecting protein folding |
| 03/03/2004 | EP1392845A2 A g-protein coupled receptor and uses therefor |
| 03/03/2004 | EP1392733A2 Mammalian tumor susceptibility gene products and their uses |
| 03/03/2004 | EP1392730A2 Transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent |
| 03/03/2004 | EP1392702A1 Compounds and methods for inhibiting mrp1 |
| 03/03/2004 | EP1392701A1 Compounds and pharmaceutical compositions for inhibiting mrp1 |
| 03/03/2004 | EP1392694A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3]pyrimidine derivatives as protein kinases inhibitors |
| 03/03/2004 | EP1392692A1 (oxo-pyrazolo 1,5a]pyrimidin-2-yl)alkyl-carboxamides |
| 03/03/2004 | EP1392685A1 Tropane alkaloid multidrug resistance inhibitors from erythroxylum pervillei and use of the same |
| 03/03/2004 | EP1392683A1 SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF |
| 03/03/2004 | EP1392677A2 Chiral broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions |
| 03/03/2004 | EP1392676A2 Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands |
| 03/03/2004 | EP1392637A2 Modulators of peroxisome proliferator activated receptors |
| 03/03/2004 | EP1392399A1 Use and compositions of antiprogestins for treatment of prostate diseases |
| 03/03/2004 | EP1392363A2 Compositions and uses of mglur5 antagonists |
| 03/03/2004 | EP1392361A1 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
| 03/03/2004 | EP1392359A2 Specific binding proteins and uses thereof |
| 03/03/2004 | EP1392355A1 Use of proteasome inhibitors to treat dry eye disorders |
| 03/03/2004 | EP1392354A2 Use of alpha-1 antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds |
| 03/03/2004 | EP1392351A2 Chemokines as adjuvants of immune response |
| 03/03/2004 | EP1392349A1 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions |
| 03/03/2004 | EP1392348A1 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
| 03/03/2004 | EP1392345A2 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
| 03/03/2004 | EP1392340A2 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof |
| 03/03/2004 | EP1392329A1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 03/03/2004 | EP1392328A2 Cancer therapy |
| 03/03/2004 | EP1392327A2 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases |